Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immuneering Corp Cl A (NQ: IMRX )

1.470 -0.070 (-4.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 184,023
Open 1.570
Bid (Size) 1.460 (3)
Ask (Size) 1.600 (10)
Prev. Close 1.540
Today's Range 1.460 - 1.570
52wk Range 1.380 - 11.92
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024
IMRX stock results show that Immuneering missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire

Performance

YTD
-79.92%
-79.92%
1 Month
-20.97%
-20.97%
3 Month
-77.73%
-77.73%
6 Month
-73.75%
-73.75%
1 Year
-83.58%
-83.58%

More News

Read More
Immuneering Recognizes Melanoma Awareness Month
From Immuneering Corporation
Via GlobeNewswire
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
From Immuneering Corporation
Via GlobeNewswire
3 Stocks Insiders Are Buying That Analysts Love
Via MarketBeat
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI
Via AB Newswire
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data
Via Benzinga
Dow Falls Over 200 Points; Adobe Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Crude Oil Edges Lower; US Consumer Sentiment Falls In March
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
What's Going On With Cancer-Focused Immuneering Stock On Thursday?
Via Benzinga
US Stocks Higher; Producer Prices Rise 0.6% In February
Via Benzinga
Topics Stocks
Exposures US Equities
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
From Immuneering Corporation
Via GlobeNewswire
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
From Immuneering Corporation
Via GlobeNewswire
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
From Immuneering Corporation
Via GlobeNewswire
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
Via FinancialNewsMedia
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
From Immuneering Corporation
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.